Lipid Profiles Impact on the Oncologic Outcome of Upper Tract Urothelial Carcinoma.

IF 2.1 Q3 ONCOLOGY
World Journal of Oncology Pub Date : 2024-04-01 Epub Date: 2024-03-21 DOI:10.14740/wjon1800
Kuan-Yi Tu, Ching-Chia Li, Wei-Ming Li, Hsin-Chih Yeh, Hung-Lung Ke, Wen-Jeng Wu, Tsu Ming Chien, Sheng-Chen Wen, Yen-Chun Wang, Hsiang-Ying Lee
{"title":"Lipid Profiles Impact on the Oncologic Outcome of Upper Tract Urothelial Carcinoma.","authors":"Kuan-Yi Tu, Ching-Chia Li, Wei-Ming Li, Hsin-Chih Yeh, Hung-Lung Ke, Wen-Jeng Wu, Tsu Ming Chien, Sheng-Chen Wen, Yen-Chun Wang, Hsiang-Ying Lee","doi":"10.14740/wjon1800","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The prognosis of upper tract urothelial carcinoma (UTUC) varies, with T3/T4 UTUC having less than 50% 5-year survival post-radical nephroureterectomy (RNU). Lipid profiles including cholesterol (CHOL), low-density lipoprotein (LDL), and triglycerides (TGs), and high-density lipoprotein (HDL) have shown correlations with oncologic outcomes in various cancers. We aimed to investigate the prognostic significance of the lipid profiles in UTUC patients who had received RNU.</p><p><strong>Methods: </strong>In this retrospective study, a total of 217 UTUC patients who underwent RNU were analyzed. Prognostic factors for overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) were assessed using Cox proportional hazards regression model and competing risk analysis.</p><p><strong>Results: </strong>The median follow-up duration was 2.36 years. Fifty-one (23.50%) of the patients experienced tumor progression, 16 (7.37%) died from UTUC, and 41 (18.89%) died from all causes during the follow-up period. Multivariate analysis revealed that elevated CHOL, low HDL, and elevated TG were linked to worse OS (P = 0.0188, 0.0002, and 0.0001, respectively). Higher CHOL, LDL, and TG, as well as lower HDL significantly affected PFS (P < 0.001 for all), and elevated CHOL and TG were associated with poorer CSS (P = 0.0033 and 0.0179). A competing risk model indicated that elevated LDL increased the risk of cancer progression (P = 0.407), with CHOL increasing the risk of UTUC-specific mortality (P = 0.0162). Limitations include retrospective design, limited, single-time sampling and relatively small sample size.</p><p><strong>Conclusions: </strong>Lipid profiles were identified as prognostic indicators for UTUC patients post-RNU. It highlights the potential importance of lipid management in improving tumor-related outcomes.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"15 2","pages":"287-297"},"PeriodicalIF":2.1000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965261/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/wjon1800","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The prognosis of upper tract urothelial carcinoma (UTUC) varies, with T3/T4 UTUC having less than 50% 5-year survival post-radical nephroureterectomy (RNU). Lipid profiles including cholesterol (CHOL), low-density lipoprotein (LDL), and triglycerides (TGs), and high-density lipoprotein (HDL) have shown correlations with oncologic outcomes in various cancers. We aimed to investigate the prognostic significance of the lipid profiles in UTUC patients who had received RNU.

Methods: In this retrospective study, a total of 217 UTUC patients who underwent RNU were analyzed. Prognostic factors for overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) were assessed using Cox proportional hazards regression model and competing risk analysis.

Results: The median follow-up duration was 2.36 years. Fifty-one (23.50%) of the patients experienced tumor progression, 16 (7.37%) died from UTUC, and 41 (18.89%) died from all causes during the follow-up period. Multivariate analysis revealed that elevated CHOL, low HDL, and elevated TG were linked to worse OS (P = 0.0188, 0.0002, and 0.0001, respectively). Higher CHOL, LDL, and TG, as well as lower HDL significantly affected PFS (P < 0.001 for all), and elevated CHOL and TG were associated with poorer CSS (P = 0.0033 and 0.0179). A competing risk model indicated that elevated LDL increased the risk of cancer progression (P = 0.407), with CHOL increasing the risk of UTUC-specific mortality (P = 0.0162). Limitations include retrospective design, limited, single-time sampling and relatively small sample size.

Conclusions: Lipid profiles were identified as prognostic indicators for UTUC patients post-RNU. It highlights the potential importance of lipid management in improving tumor-related outcomes.

血脂谱对上尿路上皮癌肿瘤结局的影响
背景:上尿路上皮癌(UTUC)的预后各不相同,T3/T4 UTUC在根治性肾切除术(RNU)后的5年生存率不到50%。包括胆固醇(CHOL)、低密度脂蛋白(LDL)、甘油三酯(TGs)和高密度脂蛋白(HDL)在内的血脂谱与各种癌症的肿瘤预后相关。我们的目的是研究接受过 RNU 治疗的 UTUC 患者的血脂状况对预后的意义:在这项回顾性研究中,我们分析了217名接受RNU治疗的UTUC患者。采用Cox比例危险回归模型和竞争风险分析评估了总生存期(OS)、癌症特异性生存期(CSS)和无进展生存期(PFS)的预后因素:中位随访时间为 2.36 年。在随访期间,51名患者(23.50%)出现肿瘤进展,16名患者(7.37%)死于UTUC,41名患者(18.89%)死于各种原因。多变量分析显示,胆固醇(Chol)升高、高密度脂蛋白(HDL)降低和总胆固醇(TG)升高与较差的OS有关(P=0.0188、0.0002和0.0001)。较高的胆固醇、低密度脂蛋白和总胆固醇以及较低的高密度脂蛋白会显著影响患者的生存期(P均<0.001),胆固醇和总胆固醇升高与较差的CSS相关(P = 0.0033和0.0179)。竞争风险模型显示,低密度脂蛋白升高会增加癌症进展的风险(P = 0.407),而胆固醇升高会增加UTUC特异性死亡的风险(P = 0.0162)。该研究的局限性包括:回顾性设计、有限的单次取样以及样本量相对较小:结论:血脂特征被认为是RNU术后UTUC患者的预后指标。这凸显了血脂管理在改善肿瘤相关预后方面的潜在重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
15.40%
发文量
37
期刊介绍: World Journal of Oncology, bimonthly, publishes original contributions describing basic research and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. The submissions can be basic research or clinical investigation oriented. This journal welcomes those submissions focused on the clinical trials of new treatment modalities for cancer, and those submissions focused on molecular or cellular research of the oncology pathogenesis. Case reports submitted for consideration of publication should explore either a novel genomic event/description or a new safety signal from an oncolytic agent. The areas of interested manuscripts are these disciplines: tumor immunology and immunotherapy; cancer molecular pharmacology and chemotherapy; drug sensitivity and resistance; cancer epidemiology; clinical trials; cancer pathology; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; gene therapy; cancer endocrinology; cancer metastasis; prevention and diagnosis of cancer; other cancer related subjects. The types of manuscripts accepted are original article, review, editorial, short communication, case report, letter to the editor, book review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信